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Lactobacillus and Bifidobacterium are two genera of gram-positive bacteria that are 
widely used as probiotic products to improve the composition of the intestinal microbiota 
but until now the difference in the number of these bacteria in patients with type 2 
diabetes mellitus and healthy people in Asia remains unclear. This study conducted a 
systematic review to analyze the differences in the number of Lactobacillus and 
Bifidobacterium bacteria in patients with type 2 diabetes and healthy people in Asia. The 
results showed that the number of Lactobacillus bacteria was higher in patients with type 
2 diabetics than in healthy people. The number of Bifidobacterium bacteria in patients 
with type 2 diabetes tended to be lower than in healthy people, although there was some 
literature stating that there was no difference in the number of Bifidobacterium bacteria 
in patients with type 2 diabetes and in healthy people. Further research on the profile of 
Lactobacillus and Bifidobacterium bacteria per type (species) specifically in people with 
type 2 diabetes and healthy people of various ethnicities in Indonesia is needed to identify 
dysbiosis in people with type 2 diabetes and determine specific microbiota therapy for 
people with type 2 diabetes. 
 
Introduction 
 Diabetes mellitus type 2 is one of the leading causes of death in Southeast Asia (1). The prevalence 
of people with type 2 diabetes mellitus in Indonesia based on Riskesdas Data also increases every year, 
wherein in 2013 it was 6.9% and increased to 10.9% in 2018 (2). Type 2 diabetes mellitus is a chronic 
disease with multifactorial causes, such as diet, lifestyle, and genetic. Several previous studies have also 
stated that the microbiota in the gastrointestinal tract is also a factor associated with type 2 diabetes 
mellitus (3). The composition of gut microbiota changes in people with type 2 diabetes mellitus. The 
number of gram-positive bacteria, such as Lactobacillus and Clostridium (phylum Firmicutes) and 
Bifidobacterium (phylum Actinobacteria) decrease. While, the number of gram-negative bacteria, such as 
phylum Bacteroidetes increase (3). A high number of gram-negative bacteria can increase the risk of macro 
and microvascular complications in people with type 2 diabetes. 
Several previous studies have explained that increasing the number of gram-positive bacteria can 
be done by giving probiotic products, such as yoghurt so that they can improve the balance of the gut 
microbiota in people with type 2 diabetes mellitus. The results of research conducted by Ejtahed et al. 
(2012) and Ruan et al. (2015) stated that there was a decrease in the value of blood glucose and insulin 
resistance in people with type 2 diabetes mellitus who consumed yoghurt through a mechanism of reducing 
oxidative stress (4,5). Generally, yoghurt contains Lactobacillus and Bifidobacterium bacteria. Previous 
research stated that increasing Lactobacillus and Bifidobacterium through yoghurt consumption has 
benefits for people with type 2 diabetes mellitus. It can produce exopolysaccharides which function as 
inhibitors of oxidative stress (6,7). However, the effectiveness of using Lactobacillus and Bifidobacterium 
yoghurt is still questionable.  A study conducted by Sato et al. (2014) showed that Lactobacillus bacteria 
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tend to increase in people with type 2 diabetes mellitus in Japan, as well as what happened in the 
population of people with type 2 diabetes mellitus in Europe (8,9). This contradiction result raises a new 
question about the composition of the microbiota (especially Lactobacillus and Bifidobacterium) among 
people with type 2 diabetes mellitus. 
Considering some of the above factors, we are interested in knowing the differences in the 
microbiota composition of Lactobacillus and Bifidobacterium in the gut between healthy individuals and 
people with type 2 diabetes mellitus in the Asian population in a systematic literature review. Consider the 
results of previous studies suggesting that the composition of Lactobacillus and Bifidobacterium in people 
with type 2 diabetes mellitus is still not known, especially among Asian include the Indonesian. Besides, the 
diet and genetics in Asian communities are different from other ethnicities so that they can affect the 
condition of the microbiota in the gut. The publication of systematic reviews on this topic among Asian 
populations is still limited. The results of this study are expecting to be one of the theories for the 
investigation of microbiota composition. Moreover, it becomes one of the bases for the development of 
alternative therapeutic products (probiotics, prebiotics, or synbiotics) that are compatible with the 




 This research conducted using a systematic literature review design or method. The search for the 
data carried out using search engines or databases such as Scopus, PubMed, Science Direct, Springer Link 
and Google Scholar. The keywords relevant that used in this research following the Boolean rule: "diabetes 
mellitus type 2 AND probiotic OR Lactobacillus OR Bifidobacterium".  
The eligibility criteria for the journals were: 1) examine the composition of the microbiota in the gut, 
both in healthy individuals and people with type 2 diabetes mellitus; 2) the research respondents are the 
Asian community or population; 3) Lactobacillus and or Bifidobacterium quantified from stool samples; 4) 
published during the last 10 years (2011-2020); 5) articles in English or Indonesian, and 6) available in full 
text. The review method of the scientific research done with the help of the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) checklist. After the search and selection process of 
literature meets the criteria, the research is continued by synthesizing and analyzing data. The summary 
made using a table containing information on the name of the researcher, research title, population, 
methods, results, and conclusions of compatible articles. The contents of the table then are discussed for the 


























Figure 1. Flowchart of Systematic Literature Search 
Articles identified from searching 
through the database 
(n = 8869) 
articles are selected after selection 
from duplication, title and abstract (n 
= 26) 
articles to be reviewed  
(n = 7) 
Articles were excluded after selection 
from duplicates, titles and abstracts  
(n = 8843) 
Articles were excluded after selection from 
full-text 
 (n = 19) 
 
Exclusion criteria:  
1)full text not available; 2)bacteria counted 
not from stool samples; 3)did not analyze 
differences in the number of bacteria 
Lactobacillus and or Bifdobacterium 
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Based on the literature search and selection guidelines, the researcher summarizes the literature 
search and selection process in Figure 1. A total of 7 articles were eligible for this review. The review listed 
in Table 1. 
 
Table 1.  Journal Reviews 
 
Study Populations 


















49 people with 
type 2 diabetes 
mellitus (T2DM), 
21 people with 
type 1 diabetes 
mellitus (T1DM), 













Lactobacillus people with T2DM : 
6,8±0,4 log10 CFU/g 
people with T1DM  : 
6,8±0,4 log10 CFU/g 
Control : 4,4±0,9 
log10 CFU/g 
p-value : <0,001* 
There was a 
significant 
difference between 
the number of 
Lactobacillus in 
people with T2DM, 
T1DM, and healthy 
people 
Bifidobacterium people with T2DM : 
5,7±0,9 log10 CFU/g 
people with T1DM  : 
5,5±0,8log10 CFU/g 
Control : 6,0±1,0 
log10 CFU/g 
p-value : 0,04* 
There was a 
significant 
difference between 
the number of 
Bifidobacterium in 
people with T2DM, 





50 people with 
















people with T2DM : 
4,9 ± 1,1 log10/g 
Control : 4,2 ± 1,2 
log10/g 
p-value : 0,0005* 
There was a 
significant 
difference between 
the number of 
Lactobacillus in 
people with T2DM 
and healthy people 
Bifidobacterium people with T2DM : 
6,8 ± 1,5 log10/g 
Control : 7,0 ± 1,1 
log10/g 
p-value : 0,482 
There was no 
significant 
difference between 
the number of 
Bifidobacterium in 
people with T2DM 





59 people with 












Bifidobacterium  people with T2DM : 
25,7 (12,4-38,5) 
(Population, % total 
sequences) 
Control: 5,5 (1,5-
12,0) (Population, % 
total sequences) 
p-value : <0,01* 
There was a 
significant 
difference between 
the number of 
Bifidobacterium in 
people with T2DM 




18 people with 
T2DM and 18 
healthy people 













people with T2DM : 
6,65E6 ± 2,02E6/g 
Control : 1,22E6 ± 
6,51E5/g 
p-value : 0,00* 
There was a 
significant 
difference between 
the number of 
Lactobacillus in 
people with T2DM 
and healthy people 
Bifidobacterium people with T2DM :  
1,82E7 ± 1,88E7/g 
Control : 5,24E8 ± 
1,36E7/g 
p-value : 0,00* 
There was a 
significant 
difference between 
the number of 
Bifidobacterium in 
people with T2DM 
and healthy people 
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Table 1.  Journal Reviews (Cont.) 
 
Study Populations 













50 people with 
type 2 diabetes 











Lactobacillus people with T2DM: 
7,0±1,5 log10 sel/g 
Control:6,4±1,2 log10 
sel/g 
p-value : <0,05*  
There was a 
significant difference 
between the number 
of Lactobacillus in 
people with T2DM 
and healthy people 
Bifidobacteri
um  
people with T2DM: 
9,2±0,8 log10 sel/g 
Control: 9,2±0,8 
log10 sel/g 
p-value : >0,05  
There was no 
significant difference 
between the number 
of Bifidobacterium in 
people with T2DM 
and healthy people 
Lê et al. 
(2013) 
50 people with 
type 2 diabetes 
mellitus and 30 
healthy people 








Lactobacillus people with T2DM: 




(control) : 6,6±0,5 
(Data after logarithm 
transformation)  
p-value: <0,0001* 
There was a 
significant difference 
between the number 
of Lactobacillus in 
people with T2DM 
and healthy people 
Bifidobacteri
um  
people with T2DM: 
10,7±0,7 (Data after 
logarithm 
transformation) 
Control : 11,6±0,9 
(Data after logarithm 
transformation)  
p-value : <0,0001* 
There was a 
significant difference 
between the number 
of Bifidobacterium in 
people with T2DM 
and healthy people 
Note: * there is a significant difference (p <0.05) 
Discussion 
Following the objectives of the study, the researchers reviewed the differences in the number of 
Lactobacillus and Bifidobacterium bacteria in healthy people and people with type 2 diabetes in Asia. 
Lactobacillus and Bifidobacterium are two genera of gram-positive bacteria that commonly exist in the 
human digestive tract (10). Four articles analyzed the difference in the number of Lactobacillus bacteria 
between people with type 2 diabetes mellitus (type 2 diabetes) and healthy people in Asia.  An article 
analyzed the difference in the number of Lactobacillus bacteria between people with type 2 diabetes, type 1 
diabetes mellitus and healthy people in Asia. All articles conclude that there are differences in the number 
of Lactobacillus bacteria between people with type 2 diabetes and healthy people and there are differences 
in the number of Lactobacillus bacteria between people with type 2 diabetes, people with type 1 diabetes, 
and healthy people. In general, all articles show that the number of Lactobacillus bacteria is higher in 
people with type 2 diabetes than in healthy people. 
According to previous research, not all bacteria from the genus Lactobacillus have a positive effect 






18 people with 












B. fragilis people with T2DM : 





p-value : 0,38  
There was no 
significant 
difference between 
the number of B. 
fragilis in people 
with T2DM and 
healthy people 
B. Longum people with T2DM : 





p-value : 0,93  
There was no 
significant 
difference between 
the number of B. 
Longum in people 
with T2DM and 
healthy people 
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glucose, while for another genus has different effects (11, 12). Based on these reasons, the researchers 
suggest further research to identify differences in the number of bacteria from the Lactobacillus genus per 
type so that the research results are detailed. 
Other possibilities could be the cause of the higher number of genus Lactobacillus bacteria in people 
with type 2 diabetes mellitus compared to healthy people. The intestinal microbiota influenced by the type 
of drug consumed in people with type 2 diabetes mellitus (13). Several previous studies or reviews stated 
that there is a tendency to decrease the number of Lactobacillus bacteria in the gastrointestinal tract of 
people with type 2 diabetes. But, this may change if the patient starts to conduct new habits such as eating 
high-probiotic foods, high-fibre foods and or taking anti-hyperglycemic drugs. High-probiotic foods such as 
yoghurt, kefir, cheese, or milk and foods high in insoluble fibre have shown to increase the number of 
Lactobacillus bacteria in the digestive tract (14).     
When viewed from the population characteristics of the articles reviewed, there is a tendency for the 
habit of eating foods high in probiotics among Iranian, Japanese, and parts of Chinese . All three populations 
of these countries have long had a culture of consuming a high probiotic diet, which probiotic products 
accessed easily from pharmacies and health facilities (22). Japan is known as the global market leader in 
the field of probiotics. Japanese usually consume products high in probiotics for health (22). The results of a 
review of research in Iran also show that Iranians have begun to realize the importance of consuming foods 
or products high in probiotics so that the need for food or probiotic products increases (23). The tradition 
of changing milk into fermented products has also long been applied in China so that Chinese people are 
most likely already accustomed to consuming fermented milk that contains probiotics, one of which is the 
genus Lactobacillus (24). These reasons can be the cause of the higher number of Lactobacillus bacteria in 
people with type 2 diabetes than in healthy people. 
The review of the number of Bifidobacterium bacteria among people with type 2 diabetes and 
healthy people in Asia obtained from 5 journals. One journal analyzed the differences in the number of 
Bifidobacterium bacteria in people with type 2 diabetes, people with type 1 diabetes, and healthy people 
showed the results that the number of Bifidobacterium was higher in healthy people than in people with 
type 2 and type 1 diabetes. Three journals concluded that there was a significant difference in the number 
of Bifidobacterium bacteria in people with type 2 diabetes and healthy people.  Moreover, two journals 
showed that the number of Bifidobacterium bacteria was higher in the control group (healthy people) 
compared to the group of people with type 2 diabetes mellitus.  Otherwise, a journal shows the opposite 
result. Two journals that analyzed the difference in the number of Bifidobacterium bacteria between the 
two groups showed insignificant differences. In general, it concluded that there is still debate about the 
number of Bifidobacterium bacteria in people with type 2 diabetes and healthy people. However, when 
compared with previous studies, it can be concluded that there is a tendency for the number of 
Bifidobacterium bacteria to be higher in the digestive tract of healthy people compared to people with type 
2 diabetes. This evidence was not remarkable because the bacteria of the genus Bifidobacterium have anti-
inflammatory effects which people with dietary habits are high in fat and people with metabolic disorders 
such as diabetes mellitus will experience a decrease in the composition of the bacterial genus 
Bifidobacterium (25,26). 
The decrease in the number or composition of Bifidobacterium bacteria in people with type 2 
diabetes may not always occur because generally, the number of each type of the genus Bifidobacterium is 
also different. Based on another article that reviewed, it showed that the number of bacteria with the 
species Bifidobacterium fragilis and Bifidobacterium longum did not differ significantly in the digestive 
tract of people with type 2 diabetes mellitus and healthy people. The results of these studies differ from the 
study of Le et al. (2013), which showed that there was a significant difference in the number of 
Bifidobacterium adolescentis bacteria in the digestive tract of people with type 2 diabetes and healthy 
people.  There is a tendency for the higher number of Bifidobacterium adolescentis in the digestive tract of 
healthy people (21). The results of the study which state that there is a significant difference between the 
number of Bifidobacterium bacteria with type 2 diabetes mellitus and healthy people are generally 
consistent with the result of the number of bacteria from the genus Bifidobacterium is higher in healthy 
people than people with type 2 diabetes (15,18). This study is indeed limited in reviewing the differences 
between Lactobacillus and Bifidobacterium bacteria because it only analyzes genus, even though the effects 
of probiotics are broad and vary depending on the probiotic type. Therefore, researchers suggest further 
research on the number of type of bacteria from the genus Bifidobacterium and Lactobacillus in people 
with type 2 diabetes mellitus and healthy people. We also recommend that microbiota-based therapy for 
people with type 2 diabetes be developed, especially from the genus Bifidobacterium and several types of 
Lactobacillus, which do have a positive effect on reducing blood glucose.  Because there has been no 
research on a topic like this in Indonesia, we also suggest that a specific study be conducted to observe the 
number of Bifidobacterium and Lactobacillus bacteria in people with type 2 diabetes mellitus and healthy 
people in Indonesia. 
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Conclusion 
This Systematic Literature Review study concludes that there is a difference in the number of 
Lactobacillus bacteria in the digestive tract of people with type 2 diabetes and healthy people in Asia 
populations. There is also a tendency for the number of Lactobacillus bacteria in the digestive tract of 
people with type 2 diabetes to be greater than in healthy people. Based on an article that reviewed, there is 
still debate about the difference in the number of Bifidobacterium bacteria in the digestive tract of people 
with type 2 diabetes and healthy people. But the results of studies show that there are differences in the 
number of Bifidobacterium bacteria in the digestive tract of people with type 2 diabetes and healthy people 
in Asian populations. It consistently shows a decrease in the number of Bifidobacterium bacteria in the 
digestive tract of people with type 2 diabetes. Further research on the profile of Lactobacillus and 
Bifidobacterium bacteria per type (species) specifically in people with type 2 diabetes and healthy people of 
various ethnicities in Indonesia is needed to identify dysbiosis in people with type 2 diabetes. Further study 
also be required to determine specific microbiota therapy for people with type 2 diabetes. 
 
Acknowledgments 
Researchers would like to thank the Ministry of Education and Culture of the Republic of Indonesia for 
the Beginner Lecturer Research Grant provided for funding this research. 
 
References  
1.  WHO. Diabetes Fakta dan Angka. 2016.  
2.  Kementerian Kesehatan RI. Laporan Nasional RISKESDAS 2018. 2018. 
3. Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and where to go? Vol. 63, 
Journal of Nutritional Biochemistry. Elsevier Inc.; 2019. p. 101–8.  
4.  Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic 
yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012 May 1;28(5):539–43.  
5.  Ruan Y, Sun J, He J, Chen F, Chen R, Chen H. Effect of probiotics on glycemic control: A systematic 
review and meta-analysis of randomized, controlled trials. PLoS One [Internet]. 2015 Jul 10 [cited 2020 
Sep 18];10(7). Available from: https://pubmed.ncbi.nlm.nih.gov/26161741/ 
6.  Prasanna PHP, Grandison AS, Charalampopoulos D. Bifidobacteria in milk products: An overview of 
physiological and biochemical properties, exopolysaccharide production, selection criteria of milk 
products and health benefits. Vol. 55, Food Research International. Elsevier Ltd; 2014. p. 247–62.  
7.  Yerlikaya O. Starter cultures used in probiotic dairy product preparation and popular probiotic dairy 
drinks. Food Sci Technol [Internet]. 2014 [cited 2020 Sep 18];34(2):221–9. Available from: 
http://dx.doi.org/10.1590/fst.2014.0050 
8.  Sato J, Kanazawa A, Ikeda F, Yoshihara T, Goto H, Abe H, et al. Gut dysbiosis and detection of “Live 
gut bacteria” in blood of Japanese patients with type 2 diabetes. Diabetes Care. 2014;37(8):2343–50.  
9.  He C, Shan Y, Song W. Targeting gut microbiota as a possible therapy for diabetes. Vol. 35, Nutrition 
Research. Elsevier Inc.; 2015. p. 361–7.  
10.  Turroni F, Ventura M, Buttó LF, Duranti S, O’Toole PW, Motherway MOC, et al. Molecular dialogue 
between the human gut microbiota and the host: A Lactobacillus and Bifidobacterium perspective 
[Internet]. Vol. 71, Cellular and Molecular Life Sciences. Springer; 2014 [cited 2020 Sep 18]. p. 183–
203. Available from: https://link.springer.com/article/10.1007/s00018-013-1318-0 
11.  Wang G, Li X, Zhao J, Zhang H, Chen W. Lactobacillus casei CCFM419 attenuates type 2 diabetes via a 
gut microbiota dependent mechanism. Food Funct [Internet]. 2017 Sep 1 [cited 2020 Sep 18];8(9):3155–
64. Available from: https://pubs.rsc.org/en/content/articlehtml/2017/fo/c7fo00593h 
12.  Yan F, Li N, Shi J, Li H, Yue Y, Jiao W, et al. Lactobacillus acidophilus alleviates type 2 diabetes by 
regulating hepatic glucose, lipid metabolism and gut microbiota in mice. Food Funct [Internet]. 2019 Sep 
1 [cited 2020 Sep 18];10(9):5804–15. Available from: 
https://pubs.rsc.org/en/content/articlehtml/2019/fo/c9fo01062a 
13.  Kałużna-Czaplińska J, Gątarek P, Chartrand MS, Dadar M, Bjørklund G. Is there a relationship between 
intestinal microbiota, dietary compounds, and obesity? Trends Food Sci Technol. 2017;70(July):105–13.  
14.  Namdag B, Batdelger A, Batsaikhan S, Chimeddorj B. Determination Result of Colonic Lactobacillus in 
Healthy Adults. 2019;5(2):149–56.  
15.  Ejtahed HS, Hoseini-Tavassol Z, Khatami S, Zangeneh M, Behrouzi A, Ahmadi Badi S, et al. Main gut 
bacterial composition differs between patients with type 1 and type 2 diabetes and non-diabetic adults. J 
Diabetes Metab Disord. 2020;19(1):265–71.  
16.  Chen P-C, Chien Y-W, Yang S-C. The Alteration of Gut Microbiota in Newly Diagnosed Type 2 Diabetic 
Patients. Nutrition. 2019;63–64:51–6.  
17.  Adachi K, Sugiyama To, Yamaguchi Y, Tamura Y, Izawa S, Hijikata Y, et al. Gut Microbiota Disorders 
39                                                                                 Kardina, et al., Lactobacillus and Bifidobacterium Bacteria profile in.. 
Copyright © 2021 Rizki Nurmalya Kardina,  Kartika Yuliani, Farah Nuriannisa 
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. 
 
Cause Type 2 Diabetes Mellitus and Homeostatic Disturbances in Gut-related Metabolism in Japanese 
Subjects. J Clin Biochem Nutr. 2019;  
18.  Sedighi M, Razavi S, Navab-Moghadam F, Khamseh ME, Alaei-Shahmiri F, Mehrtash A, et al. 
Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals. Microb 
Pathog [Internet]. 2017;111:362–9. Available from: https://doi.org/10.1016/j.micpath.2017.08.038 
19.  Navab-Moghadam F, Sedighi M, Khamseh ME, Alaei-Shahmiri F, Talebi M, Razavi S, et al. The 
association of type II diabetes with gut microbiota composition. Microb Pathog [Internet]. 
2017;110:630–6. Available from: http://dx.doi.org/10.1016/j.micpath.2017.07.034 
20.  Sato J, Kanazawa A, Ikeda F, Yoshihara T, Goto H, Abe H, et al. Gut dysbiosis and detection of “Live 
gut bacteria” in blood of Japanese patients with type 2 diabetes. Diabetes Care [Internet]. 2014 Aug 1 
[cited 2020 Sep 18];37(8):2343–50. Available from: http://care.diabetesjournals.org/lookup/ 
21.  Lê KA, Li Y, Xu X, Yang W, Liu T, Zhao X, et al. Alterations in fecal Lactobacillus and Bifidobacterium 
species in type 2 diabetic patients in Southern China population. Front Physiol. 2013;3 JAN(January):1–
6.  
22.  Amagase H. Current marketplace for probiotics: A Japanese perspective. Clin Infect Dis. 
2008;46(SUPPL. 2):73–5.  
23.  Mahmoudi R, Tahapour K, Farhoodi A, Fakhri O, Kaboudari A. A Review on Probiotic Dairy Products 
as Functional Foods Reported from Iran. Int J Food Nutr Saf. 2015;6(3):94–105.  
24.  Mullie P, Guelinckx I, Clarys P, Degrave E, Hulens M, Vansant G. Cultural, socioeconomic and 
nutritional determinants of functional food consumption patterns. Eur J Clin Nutr [Internet]. 2009 Aug 
26 [cited 2020 Sep 18];63(11):1290–6. Available from: www.nature.com/ejcn 
25.  Kawasaki S, Watanabe M, Fukiya S, Yokota A. Stress Responses of Bifidobacteria: Oxygen and Bile 
Acid as the Stressors. In: The Bifidobacteria and Related Organisms. Elsevier; 2018. p. 131–43.  
26.  Lin Y, Ren Y, Zhang Y, Zhou J, Zhou F, Zhao Q, et al. Protective role of nano-selenium-enriched 
Bifidobacterium longum in delaying the onset of streptozotocin-induced diabetes. R Soc Open Sci 
[Internet]. 2018 Dec 12 [cited 2020 Sep 18];5(12):181156. Available from: 
https://royalsocietypublishing.org/doi/10.1098/rsos.181156 
 
 
